AJP - Renal Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Renal Physiol 292: F1291-F1301, 2007. First published December 12, 2006; doi:10.1152/ajprenal.00327.2005
0363-6127/07 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/4/F1291    most recent
00327.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by El Chaar, M.
Right arrow Articles by Felsen, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by El Chaar, M.
Right arrow Articles by Felsen, D.

Effect of combination therapy with enalapril and the TGF-beta antagonist 1D11 in unilateral ureteral obstruction

Maher El Chaar,1 Jie Chen,1 Surya V. Seshan,2 Sharda Jha,3 Ingride Richardson,1 Steven R. Ledbetter,3 E. D. Vaughan, Jr,2 Dix P. Poppas,1 and Diane Felsen1

1Institute for Pediatric Urology-Weill Cornell Medical College, 2Department of Pathology, Weill Cornell Medical College, New York, New York; and 3The Genzyme Corporation, Framingham, Massachusetts

Submitted 15 August 2005 ; accepted in final form 29 November 2006

In unilateral ureteral obstruction (UUO), the kidney is characterized by increased fibrosis and apoptosis. Both transforming growth factor-beta (TGF-beta) and ANG II have been implicated, and ANG II may mediate its effects through TGF-beta. Previous studies demonstrated amelioration of renal damage when either TGF-beta or ANG II has been individually targeted. In this study, we sought to determine whether combining 1D11 (monoclonal antibody to TGF-beta) and an ACE inhibitor, enalapril, would be more effective in UUO than either individual treatment, as has been shown in diabetic and glomerulonephritic models. Rats underwent UUO and were given either control monoclonal antibody, 1D11 or enalapril, or 1D11/enalapril combination, for 14 days. Kidneys were harvested and examined for fibrosis [trichrome; collagen (real-time PCR, Sircol assay) and fibroblast-specific protein expression (immunohistochemistry), apoptosis (TUNEL), macrophage infiltration (immunohistochemistry), and TGF-beta expression (real-time PCR and tubular localization with immunohistochemistry)]. UUO was found to induce fibrosis, apoptosis, macrophage infiltration, and TGF-beta expression in the obstructed kidney. Administration of either 1D11 or enalapril individually significantly decreased all these changes; when 1D11 and enalapril were combined, there was little additive effect, and the combination did not provide full protection against damage. The results demonstrate that, for the most part, combination therapy is not additive in UUO. This could be due to the continued presence of a physical obstruction or to biochemical differences between UUO and other renal disease models. Furthermore, it suggests that other targets may be amenable to pharmacological manipulation in UUO.

fibrosis; apoptosis; transforming growth factor-beta; converting enzyme inhibitor



Address for reprint requests and other correspondence: D. Felsen, Dept. of Urology, Weill Cornell Medical College, Box 94, 1300 York Ave., New York, NY 10021 (e-mail: dfelsen{at}med.cornell.edu)




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
Z. Kassiri, V. Defamie, M. Hariri, G. Y. Oudit, S. Anthwal, F. Dawood, P. Liu, and R. Khokha
Simultaneous Transforming Growth Factor {beta}-Tumor Necrosis Factor Activation and Cross-talk Cause Aberrant Remodeling Response and Myocardial Fibrosis in Timp3-deficient Heart
J. Biol. Chem., October 23, 2009; 284(43): 29893 - 29904.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
Y. Mizuguchi, J. Chen, S. V. Seshan, D. P. Poppas, H. H. Szeto, and D. Felsen
A novel cell-permeable antioxidant peptide decreases renal tubular apoptosis and damage in unilateral ureteral obstruction
Am J Physiol Renal Physiol, November 1, 2008; 295(5): F1545 - F1553.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
P. Boor, K. Sebekova, T. Ostendorf, and J. Floege
Treatment targets in renal fibrosis
Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3391 - 3407.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.